Status:
COMPLETED
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
Lead Sponsor:
Bayer
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
6-48 years
Phase:
NA
Brief Summary
To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).
Eligibility Criteria
Inclusion
- Children with normal or dry skin and a history of mild to moderate AD, but without any signs or symptoms within the last month prior to enrollment
- Skin type I - VI according to Fitzpatrick skin classification
- Aged 6 months to 48 months
Exclusion
Key Trial Info
Start Date :
September 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 2 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03441568
Start Date
September 26 2018
End Date
August 2 2019
Last Update
July 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West Timperley Medical Centre
Altrincham, United Kingdom, WA14 5PF